Emergent BioSolutions Inc. (EBS)
B
Pipeline Grade
Financial Position (from SEC Filings)
$161.5M
Cash & Equivalents
$33.8M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$415M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SOMATROPIN
ACCRETROPIN |
NDA | Adenoviral Infection, Anthrax, Anthrax Infection, Arthritis, Rheumatoid, Bacillus Anthracis (Anthrax) Infection, Bird Flu, Botulism, Chikungunya, Chikungunya Virus, Chikungunya Virus Infection, Cholera, Cholera (Disorder), Complication of Smallpox Vaccination, Congenital Abnormalities, COVID-19, Cyanide Poisoning, Healthy, Healthy Volunteer, Healthy Volunteers, HIV Vaccine, Human Influenza, Infections, Bacterial, Influenza, Influenza A H1N1, Influenza A H3N2, Inhalational Anthrax, Myocarditis, Opioid Overdose, Pericarditis, Pregnancy Complications, Pregnancy Outcome, SARS-CoV-2 Infection, Smallpox, Smallpox Vaccine Adverse Reaction, Symptoms of Inhalational Anthrax, T Cell Lymphoma, Therapeutic Treatment of Inhalation Anthrax, Tuberculosis, Typhoid, Typhoid Fever, Vaccine Response, Viral Infection, Zika Virus, Zika Virus Disease, Zika Virus Infection |
Upcoming Catalysts
No upcoming catalysts detected for this company.